Form 4: Bionano COO's Future RSU Tax Withholding Reported

Bionano Genomics' Chief Operating Officer, Mark Oldakowski, reported the future withholding of 59 common shares on September 11, 2025, to cover tax obligations from a vested RSU award.

Summary

• Mark Oldakowski, Chief Operating Officer of Bionano Genomics, Inc. (BNGO), filed a Form 4.
• The filing reports a transaction scheduled for September 11, 2025, related to the vesting of an RSU award.
• 59 shares of common stock will be withheld by the issuer to satisfy tax withholding obligations upon the settlement of the RSU award.
• This RSU award was originally granted on September 11, 2023, and vested on September 11, 2025.
• The shares were valued at $4.06 for the purpose of this tax withholding transaction.
• Following this reported transaction, Mr. Oldakowski will beneficially own 915 shares of common stock directly.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned transaction for tax withholding related to an executive's RSU vesting, which is a standard compensation practice and does not indicate any significant positive or negative operational or financial developments for the company.

Positives

• Indicates the vesting of an RSU award for a key executive, reflecting a component of executive compensation.

Negatives

• A small number of shares (59) were withheld, representing a minor reduction in the executive's direct beneficial ownership for tax purposes.

Future Outlook

The filing details a pre-planned future transaction on September 11, 2025, related to the vesting of an RSU award and subsequent tax withholding, which is a routine compensation event and does not provide broader company outlook.

Management Comments

• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

The withholding of shares for tax obligations upon RSU vesting is a standard practice in executive compensation across various industries, particularly for publicly traded companies. It reflects the settlement of equity awards as part of an executive's compensation package.

Comparison to Industry Standards

• The mechanism of withholding shares to cover tax liabilities upon RSU vesting is a common and widely accepted practice in corporate compensation, aligning with industry standards for equity-based awards.
• Many companies, including peers in the biotechnology and genomics sectors, utilize similar methods for settling RSU awards and managing executive tax obligations.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, pre-planned compensation event and tax withholding, not a discretionary market sale.
• Employees: Reflects standard executive compensation practices, which can be a factor in talent retention and motivation.

Next Steps

• The reported transaction of share withholding for tax purposes is scheduled to occur on September 11, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned tax withholding event for an executive's RSU award, which is a standard part of compensation and does not provide new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation. The transaction is not indicative of discretionary selling or buying based on new material information.

Keywords

Bionano Genomics, BNGO, Form 4, insider transaction, RSU, stock withholding, executive compensation, Mark Oldakowski